Aarti Drugs Ltd. Financials: Quarterly Results
Revenue
721.06
Cr.
PAT
55.26
Cr.
EBITDA
78.52
Cr.
Aarti Drugs Ltd. Q3FY26 Financial Metrics
| Indicator | Mar-26 | Dec-25 | Sep-25 | Jun-25 | Mar-25 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 720.30 | 601.71 | 652.79 | 590.51 | 676.76 |
| Total Income From Operations (Cr.) | 720.30 | 601.71 | 652.79 | 590.51 | 676.76 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 78.52 | 38.32 | 68.11 | 59.67 | 80.31 |
| P/L Before Exceptional Items & Tax (Cr.) | 70.36 | 29.03 | 60.41 | 51.11 | 71.15 |
| P/L After Tax from Ordinary Activities (Cr.) | 55.26 | 40.55 | 45.16 | 53.97 | 62.77 |
| Net Profit/Loss For the Period (Cr.) | 55.26 | 40.55 | 45.16 | 53.97 | 62.77 |
| Basic EPS | 6.05 | 4.44 | 4.95 | 5.91 | 6.88 |
FAQs
Aarti Drugs Ltd. announced its quarterly results for Q3 FY2026 on February 4, 2026.
In Q3 FY2026, Aarti Drugs Ltd. are as follows:
Revenue: ₹721.06 crore
Net Profit: ₹55.26 crore.
For Q3 FY2026, Aarti Drugs Ltd. posted ₹721.06 crore in revenue and ₹55.26 crore in net profit.
Past quarterly results for Aarti Drugs Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.